We are live on
!
Find out more
GPP
Great Point Partners Portfolio holdings
AUM
$435M
1-Year Est. Return
318.81%
This Fund
S&P 500
This Quarter
Est. Return
-10.43%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$957M
AUM Growth
-$191M
(-17%)
Cap. Flow
-$30.2M
Cap. Flow
% of AUM
-3.16%
Top 10 Holdings %
Top 10 Hldgs %
64.82%
Holding
49
New
12
Increased
12
Reduced
7
Closed
13
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
SAGE
Sage Therapeutics
SAGE
|
+$59.6M |
| 2 |
ABMD
Abiomed Inc
ABMD
|
+$35.9M |
| 3 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
+$32.6M |
| 4 |
Acadia Pharmaceuticals
ACAD
|
+$30.7M |
| 5 |
CNST
Constellation Pharmaceuticals, Inc.
CNST
|
+$29.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Iovance Biotherapeutics
IOVA
|
+$69.6M |
| 2 |
MNTA
Momenta Pharmaceuticals, Inc.
MNTA
|
+$50.4M |
| 3 |
DERM
Dermira, Inc.
DERM
|
+$39.7M |
| 4 |
TG Therapeutics
TGTX
|
+$36.4M |
| 5 |
XLRN
Acceleron Pharma
XLRN
|
+$36.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 90.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Cytokinetics
CYTK
$10.5B
| $7.83M | 0.82% |
664,097
+504,024
| +315% | +$6.43M |
|
|
VRAY
27
DELISTED
ViewRay, Inc.
VRAY
| $6.93M | 0.72% |
2,773,811
+1,058,658
| +62% | +$3M |
|
28
Liquidia Corp
LQDA
$7.48B
| $6.02M | 0.63% |
1,277,955
| – | – |
|
29
Axsome Therapeutics
AXSM
$11.2B
| $5.89M | 0.62% |
100,100
+99,846
| +39,309% | +$8.14M |
|
30
Arvinas
ARVN
$518M
| $4.77M | 0.5% |
118,330
-431,670
| -78% | -$20.2M |
|
|
YARW
31
Yarrow Bioscience, Inc. Common Stock
YARW
$23.4M
| $4.43M | 0.46% |
459
| – | – |
|
|
32
CALL
Arvinas
ARVN
$518M
| $4.17M | 0.44% |
+103,500
| New | +$4.84M |
|
|
SGMO
33
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $4.04M | 0.42% |
+633,505
| New | +$4.7M |
|
34
Kura Oncology
KURA
$800M
| $1.79M | 0.19% |
179,700
-674,077
| -79% | -$7.72M |
|
35
CytomX Therapeutics
CTMX
$675M
| $1.07M | 0.11% |
+139,718
| New | +$974K |
|
36
Neurogene
NGNE
$656M
| $459K | 0.05% |
+2,017
| New | +$415K |
|
37
Atara Biotherapeutics
ATRA
$75.5M
| – | – |
-2,800
| Closed | -$1.15M |
|
38
CALL
Aurinia Pharmaceuticals
AUPH
$1.91B
| – | – |
-1,000,000
| Closed | -$20.3M |
|
|
39
CALL
Axsome Therapeutics
AXSM
$11.2B
| – | – |
-727,200
| Closed | -$75.2M |
|
40
BridgeBio Pharma
BBIO
$15.7B
| – | – |
-78,400
| Closed | -$2.75M |
|
41
DexCom
DXCM
$32.2B
| – | – |
-104,400
| Closed | -$5.71M |
|
|
GNFT
42
DELISTED
Genfit
GNFT
| – | – |
-207,766
| Closed | -$4.13M |
|
43
Insmed
INSM
$21.4B
| – | – |
-97,359
| Closed | -$2.33M |
|
44
Ionis Pharmaceuticals
IONS
$8.6B
| – | – |
-65,000
| Closed | -$3.93M |
|
|
OPTN
45
DELISTED
OptiNose
OPTN
| – | – |
-78,789
| Closed | -$10.9M |
|
46
Tandem Diabetes Care
TNDM
$1.34B
| – | – |
-250,000
| Closed | -$14.9M |
|
|
DERM
47
DELISTED
Dermira, Inc.
DERM
| – | – |
-2,621,333
| Closed | -$39.7M |
|
|
ZGNX
48
CALL
DELISTED
Zogenix, Inc.
ZGNX
| – | – |
-250,000
| Closed | -$13M |
|
|
ZGNX
49
DELISTED
Zogenix, Inc.
ZGNX
| – | – |
-420,000
| Closed | -$21.9M |
|
Similar funds
GDS
JWM
SWG
SCP
VIM
VDBMI
ACG
TECP
Great Point Partners's Q1 2020 Portfolio in Review
As of Q1 2020, Great Point Partners held 49 positions worth $957M, down 17% from $1.15B the previous quarter. Its ten largest holdings account for 65% of the portfolio.
Great Point Partners withdrew a net $30.2M in Q1 2020, closing 13 positions and reducing 7 holdings. Its most notable exit was Dermira, Inc., an estimated $39.7M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 86% a quarter earlier.
Against the trend, Great Point Partners opened a new position in Abiomed Inc worth $31.4M.
- Great Point Partners's largest Q1 2020 buy was Abiomed Inc: 216,144 shares worth $31.4M.
- Great Point Partners added most to Sage Therapeutics in Q1 2020, an estimated $59.6M increase.
- Great Point Partners's biggest Q1 2020 reduction was Iovance Biotherapeutics, cutting an estimated $69.6M.
- Great Point Partners fully exited Dermira, Inc. in Q1 2020, selling an estimated $39.7M.
- Great Point Partners's ten largest holdings make up 65% of its $957M portfolio in Q1 2020.
- Great Point Partners opened 12 new positions and closed 13 in Q1 2020.
- Great Point Partners's portfolio value fell 17% quarter-over-quarter to $957M.
Based on Great Point Partners's 13F filing for Q1 2020, filed 15 May 2020.